ChemPartner PharmaTech Co Ltd (300149) - Net Assets
Based on the latest financial reports, ChemPartner PharmaTech Co Ltd (300149) has net assets worth CN¥1.26 Billion CNY (≈ $184.71 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.98 Billion ≈ $289.82 Million USD) and total liabilities (CN¥718.31 Million ≈ $105.11 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300149 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.26 Billion |
| % of Total Assets | 63.73% |
| Annual Growth Rate | 26.03% |
| 5-Year Change | -49.52% |
| 10-Year Change | 71.05% |
| Growth Volatility | 116.03 |
ChemPartner PharmaTech Co Ltd - Net Assets Trend (2007–2024)
This chart illustrates how ChemPartner PharmaTech Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore ChemPartner PharmaTech Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for ChemPartner PharmaTech Co Ltd (2007–2024)
The table below shows the annual net assets of ChemPartner PharmaTech Co Ltd from 2007 to 2024. For live valuation and market cap data, see ChemPartner PharmaTech Co Ltd (300149) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.24 Billion ≈ $181.17 Million |
-15.25% |
| 2023-12-31 | CN¥1.46 Billion ≈ $213.77 Million |
-38.77% |
| 2022-12-31 | CN¥2.39 Billion ≈ $349.14 Million |
+19.95% |
| 2021-12-31 | CN¥1.99 Billion ≈ $291.06 Million |
-18.89% |
| 2020-12-31 | CN¥2.45 Billion ≈ $358.86 Million |
+6.47% |
| 2019-12-31 | CN¥2.30 Billion ≈ $337.05 Million |
+4.48% |
| 2018-12-31 | CN¥2.20 Billion ≈ $322.59 Million |
+163.87% |
| 2017-12-31 | CN¥835.45 Million ≈ $122.25 Million |
+8.51% |
| 2016-12-31 | CN¥769.93 Million ≈ $112.67 Million |
+6.37% |
| 2015-12-31 | CN¥723.81 Million ≈ $105.92 Million |
+3.92% |
| 2014-12-31 | CN¥696.53 Million ≈ $101.92 Million |
+3.91% |
| 2013-12-31 | CN¥670.29 Million ≈ $98.08 Million |
+4.59% |
| 2012-12-31 | CN¥640.90 Million ≈ $93.78 Million |
+4.82% |
| 2011-12-31 | CN¥611.46 Million ≈ $89.48 Million |
+7.03% |
| 2010-12-31 | CN¥571.30 Million ≈ $83.60 Million |
+464.19% |
| 2009-12-31 | CN¥101.26 Million ≈ $14.82 Million |
+73.52% |
| 2008-12-31 | CN¥58.36 Million ≈ $8.54 Million |
+140.62% |
| 2007-12-31 | CN¥24.25 Million ≈ $3.55 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ChemPartner PharmaTech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4328.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥1.89 Billion | 156.07% |
| Total Equity | CN¥1.21 Billion | 100.00% |
ChemPartner PharmaTech Co Ltd Competitors by Market Cap
The table below lists competitors of ChemPartner PharmaTech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Thurgauer Kantonalbank
SW:TKBP
|
$728.00 Million |
|
Barclays PLC
LSE:BARC
|
$728.12 Million |
|
Thermador Groupe SA
PA:THEP
|
$728.15 Million |
|
Shenzhen Comix Group Co Ltd
SHE:002301
|
$728.30 Million |
|
Top Resource Conservation Engineering Co Ltd
SHE:300332
|
$727.92 Million |
|
Gresgying Digital Energy Technology Co Ltd
SHG:600212
|
$727.58 Million |
|
Mobilicom Limited Warrants
NASDAQ:MOBBW
|
$727.58 Million |
|
Turkiye Sinai Kalkinma Bankasi AS
IS:TSKB
|
$727.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ChemPartner PharmaTech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,436,646,600 to 1,213,861,297, a change of -222,785,303 (-15.5%).
- Net loss of 226,474,828 reduced equity.
- Dividend payments of 2,876,300 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-226.47 Million | -18.66% |
| Dividends Paid | CN¥2.88 Million | -0.24% |
| Other Changes | CN¥6.57 Million | +0.54% |
| Total Change | CN¥- | -15.51% |
Book Value vs Market Value Analysis
This analysis compares ChemPartner PharmaTech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.20x to 4.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.92 | CN¥9.99 | x |
| 2018-12-31 | CN¥4.38 | CN¥9.99 | x |
| 2019-12-31 | CN¥4.59 | CN¥9.99 | x |
| 2020-12-31 | CN¥4.86 | CN¥9.99 | x |
| 2021-12-31 | CN¥3.93 | CN¥9.99 | x |
| 2022-12-31 | CN¥4.73 | CN¥9.99 | x |
| 2023-12-31 | CN¥2.87 | CN¥9.99 | x |
| 2024-12-31 | CN¥2.44 | CN¥9.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ChemPartner PharmaTech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -23.34%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 1.64x
- Recent ROE (-18.66%) is below the historical average (5.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 49.81% | 18.41% | 0.96x | 2.82x | CN¥9.57 Million |
| 2008 | 39.86% | 23.88% | 1.12x | 1.49x | CN¥17.36 Million |
| 2009 | 29.03% | 29.32% | 0.74x | 1.35x | CN¥19.27 Million |
| 2010 | 5.91% | 27.26% | 0.21x | 1.03x | CN¥-23.38 Million |
| 2011 | 4.66% | 16.56% | 0.26x | 1.07x | CN¥-31.47 Million |
| 2012 | 5.72% | 14.78% | 0.36x | 1.08x | CN¥-26.42 Million |
| 2013 | 6.14% | 15.48% | 0.36x | 1.09x | CN¥-24.93 Million |
| 2014 | 6.03% | 14.62% | 0.38x | 1.10x | CN¥-26.83 Million |
| 2015 | 8.22% | 18.83% | 0.42x | 1.04x | CN¥-12.90 Million |
| 2016 | 8.44% | 25.12% | 0.33x | 1.03x | CN¥-12.01 Million |
| 2017 | 7.12% | 20.99% | 0.26x | 1.29x | CN¥-23.35 Million |
| 2018 | 7.36% | 16.16% | 0.30x | 1.53x | CN¥-57.93 Million |
| 2019 | 6.06% | 10.46% | 0.35x | 1.64x | CN¥-90.27 Million |
| 2020 | 6.37% | 10.43% | 0.36x | 1.70x | CN¥-88.24 Million |
| 2021 | -20.48% | -23.79% | 0.40x | 2.15x | CN¥-598.69 Million |
| 2022 | 16.03% | 28.54% | 0.35x | 1.62x | CN¥142.43 Million |
| 2023 | -63.81% | -80.53% | 0.47x | 1.69x | CN¥-1.06 Billion |
| 2024 | -18.66% | -23.34% | 0.49x | 1.64x | CN¥-347.86 Million |
Industry Comparison
This section compares ChemPartner PharmaTech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $3,235,766,232
- Average return on equity (ROE) among peers: 10.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ChemPartner PharmaTech Co Ltd (300149) | CN¥1.26 Billion | 49.81% | 0.57x | $727.95 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $120.90 Million | 18.20% | 3.20x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $7.42 Billion | 8.25% | 0.16x | $1.66 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $134.48 Million | 6.06% | 3.14x | $443.33 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $833.76 Million | -21.21% | 0.06x | $438.41 Million |
| Chengzhi Shareholding Co Ltd (000990) | $18.46 Billion | 5.46% | 0.32x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $2.58 Billion | 14.36% | 0.06x | $3.86 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $758.10 Million | 18.96% | 0.52x | $1.19 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $5.40 Billion |
| Baolingbao Biology Co Ltd (002286) | $817.45 Million | 8.24% | 0.36x | $572.48 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $396.33 Million | 29.23% | 0.30x | $1.90 Billion |
About ChemPartner PharmaTech Co Ltd
Chempartner Pharmatech Co., Ltd. engages in the microecological nutrition and healthcare businesses worldwide. The company operates in two segments, Microecological Nutrition and Medical Business; and Pharmaceutical Research and Development Service and Production Outsourcing Business. It offers prebiotic products and the provision of microecological medical services. The company provides comprehe… Read more